Streetbeat News

Analyst Ratings

CRNX

HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Crinetics Pharmaceuticals (NASDAQ:CRNX), but has lowered the price target from $35 to $33.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:12 am

RVNC

HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Revance Therapeutics (NASDAQ:RVNC) but lowers the price target from $48 to $41.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:12 am

VCYT

Needham analyst Mike Matson maintains a 'Buy' rating on Veracyte (NASDAQ:VCYT) and raises the price target from $34 to $35.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:11 am

URG

HC Wainwright & Co. analyst Heiko Ihle has reiterated a 'Buy' rating on Ur-Energy (AMEX:URG) and maintained a price target of $2.8.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:09 am

EXK

HC Wainwright & Co. analyst Heiko Ihle maintains a 'Buy' rating on Endeavour Silver (NYSE:EXK), but lowers the price target from $8 to $7.75.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:07 am

BITF

HC Wainwright & Co. analyst Kevin Dede maintains a 'Buy' rating on Bitfarms (NASDAQ:BITF) and raises the price target from $2 to $3.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:06 am

CECO

HC Wainwright & Co. analyst Amit Dayal has reiterated a 'Buy' rating on CECO Environmental (NASDAQ:CECO) and maintained a price target of $22.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:05 am

MARA

HC Wainwright & Co. analyst Kevin Dede has reiterated a 'Buy' rating on Marathon Digital Holdings (NASDAQ:MARA) and maintained a $20 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:04 am

PSNL

Needham analyst Mike Matson has reiterated a 'Buy' rating on Personalis (NASDAQ:PSNL) and maintained a price target of $7.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:03 am

GDRX

GoodRx Holdings reported Q2 adjusted earnings of $0.07 per share, beating the analyst consensus estimate of $0.06 by 16.67%. The company's quarterly sales were $189.70 million, surpassing the analyst consensus estimate of $186.82 million by 1.54%. However, this represents a 1.09% decrease compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 10:03 am